What is the share price of Orchid Pharma Ltd (ORCHPHARMA) today?
The share price of ORCHPHARMA as on 5th December 2025 is ₹860. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Orchid Pharma Ltd (ORCHPHARMA) share?
The past returns of Orchid Pharma Ltd (ORCHPHARMA) share are- Past 1 week: -3.11%
- Past 1 month: 9.93%
- Past 3 months: 19.89%
- Past 6 months: 19.51%
- Past 1 year: -49.13%
- Past 3 years: 116.10%
- Past 5 years: 1578.27%
What are the peers or stocks similar to Orchid Pharma Ltd (ORCHPHARMA)?
The peers or stocks similar to Orchid Pharma Ltd (ORCHPHARMA) include:What is the market cap of Orchid Pharma Ltd (ORCHPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Orchid Pharma Ltd (ORCHPHARMA) is ₹4387.96 Cr as of 5th December 2025.What is the 52 week high and low of Orchid Pharma Ltd (ORCHPHARMA) share?
The 52-week high of Orchid Pharma Ltd (ORCHPHARMA) is ₹1997.40 and the 52-week low is ₹603.80.What is the PE and PB ratio of Orchid Pharma Ltd (ORCHPHARMA) stock?
The P/E (price-to-earnings) ratio of Orchid Pharma Ltd (ORCHPHARMA) is 44.03. The P/B (price-to-book) ratio is 3.46.Which sector does Orchid Pharma Ltd (ORCHPHARMA) belong to?
Orchid Pharma Ltd (ORCHPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Orchid Pharma Ltd (ORCHPHARMA) shares?
You can directly buy Orchid Pharma Ltd (ORCHPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Orchid Pharma Ltd
ORCHPHARMA Share Price
860.000.60% (-5.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ORCHPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ORCHPHARMA Performance & Key Metrics
ORCHPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 83.96 | 3.46 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
ORCHPHARMA Company Profile
Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
ORCHPHARMA Sentiment Analysis
ORCHPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ORCHPHARMA Stock Summary · August 2025
Orchid Pharma's recent financial performance reflects a challenging landscape, with a notable 29% year-over-year decline in sales driven by a global slowdown in the antibiotics market. Despite these pressures, the company has maintained gross margins around 42% through disciplined pricing and cost optimization. Strategic initiatives, including the acquisition of global rights to Enmetazobactam, position Orchid for future growth, with anticipated royalty income expected to enhance revenue potential. However, regulatory hurdles and market dynamics, such as price wars and weak demand, necessitate careful planning and operational discipline. While cautious optimism surrounds potential recovery in demand, the company remains focused on long-term strategies to solidify its market position amidst ongoing challenges.
ORCHPHARMA Stock Growth Drivers
ORCHPHARMA Stock Growth Drivers
7Acquisition of Enmetazobactam
Orchid Pharma has successfully acquired the global rights to Enmetazobactam and the trademark Exblifep from
Steady Performance of Domestic Brand Orblicef
Orchid's domestic brand, Orblicef, is performing steadily, supported by extensive hospital coverage and targeted engagement
ORCHPHARMA Stock Challenges
ORCHPHARMA Stock Challenges
5Significant Sales Decline
Orchid Pharma reported a significant decline in sales for Q1 FY '26, with figures dropping
Challenging Market Conditions
The current market environment is described as challenging, with ongoing issues such as price wars
ORCHPHARMA Forecast
ORCHPHARMA Forecasts
Price
Revenue
Earnings
ORCHPHARMA Share Price Forecast
ORCHPHARMA Share Price Forecast
2025
Current
₹865.15
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹865.15
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ORCHPHARMA Company Revenue Forecast
ORCHPHARMA Company Revenue Forecast
2025
Current
₹949.40
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹949.40
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
ORCHPHARMA Stock EPS (Earnings Per Share) Forecast
ORCHPHARMA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹19.65
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹19.65
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ORCHPHARMA
ORCHPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
ORCHPHARMA Income Statement
ORCHPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 823.83 | 703.29 | 817.84 | 508.08 | 465.27 | 627.03 | 724.54 | 850.23 | 949.40 | 855.89 | ||||||||||
Raw Materials | 373.85 | 342.63 | 263.14 | 221.68 | 245.60 | 340.62 | 406.10 | 528.35 | 588.07 | 754.23 | ||||||||||
| Power & Fuel Cost | 54.33 | 50.69 | 48.76 | 47.44 | 39.31 | 52.74 | 61.26 | 62.92 | 64.98 | |||||||||||
| Employee Cost | 79.41 | 86.22 | 82.28 | 74.86 | 67.11 | 63.28 | 65.35 | 69.64 | 86.36 | |||||||||||
| Selling & Administrative Expenses | 104.80 | 81.40 | 55.19 | 63.82 | 36.63 | 41.92 | 34.96 | 53.17 | 54.76 | |||||||||||
| Operating & Other expenses | 267.39 | 97.74 | 162.43 | 107.19 | 32.04 | 6.42 | 20.71 | -5.77 | 10.18 | |||||||||||
EBITDA | -55.95 | 44.61 | 206.04 | -6.91 | 44.58 | 122.05 | 136.16 | 141.92 | 145.05 | 101.66 | ||||||||||
| Depreciation/Amortization | 141.05 | 133.31 | 129.94 | 117.93 | 108.92 | 87.02 | 54.79 | 33.24 | 34.55 | 35.03 | ||||||||||
| PBIT | -197.00 | -88.70 | 76.10 | -124.84 | -64.34 | 35.03 | 81.37 | 108.68 | 110.50 | 66.63 | ||||||||||
| Interest & Other Items | 346.77 | 310.26 | 6.69 | 6.23 | 52.21 | 33.46 | 32.90 | 16.74 | 14.93 | 14.71 | ||||||||||
| PBT | -543.77 | -398.96 | 69.41 | -131.07 | -116.55 | 1.57 | 48.47 | 91.94 | 95.57 | 51.92 | ||||||||||
| Taxes & Other Items | -48.34 | -46.19 | 0.00 | 0.00 | 0.00 | 3.52 | 2.15 | -0.22 | -4.09 | -0.34 | ||||||||||
| Net Income | -495.43 | -352.77 | 69.41 | -131.07 | -116.55 | -1.95 | 46.32 | 92.16 | 99.66 | 52.26 | ||||||||||
| EPS | -55.69 | -39.65 | 7.80 | -20.20 | -28.55 | -0.48 | 11.35 | 20.14 | 19.65 | 10.30 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ORCHPHARMA Company Updates
FY 2026FY 2026
Investor Presentation
Nov 11PDF
Aug 12PDF
ORCHPHARMA Stock Peers
ORCHPHARMA Past Performance & Peer Comparison
ORCHPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Orchid Pharma Ltd | 44.03 | 3.46 | — |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
ORCHPHARMA Stock Price Comparison
Compare ORCHPHARMA with any stock or ETFCompare ORCHPHARMA with any stock or ETF
ORCHPHARMA
ORCHPHARMA Holdings
ORCHPHARMA Shareholdings
ORCHPHARMA Promoter Holdings Trend
ORCHPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ORCHPHARMA Institutional Holdings Trend
ORCHPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ORCHPHARMA Shareholding Pattern
ORCHPHARMA Shareholding Pattern
ORCHPHARMA Shareholding History
ORCHPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in ORCHPHARMA
Mutual Funds Invested in ORCHPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Orchid Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 5.7369% | Percentage of the fund’s portfolio invested in the stock 0.83% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/118 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6399% | Percentage of the fund’s portfolio invested in the stock 0.36% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 75/80 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4151% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/68 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ORCHPHARMA stock
smallcases containing ORCHPHARMA stock
Looks like this stock is not in any smallcase yet.
ORCHPHARMA Events
ORCHPHARMA Events
ORCHPHARMA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ORCHPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ORCHPHARMA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ORCHPHARMA has not given any dividends in last 5 years
ORCHPHARMA Dividends
ORCHPHARMA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeORCHPHARMA Stock News & Opinions
ORCHPHARMA Stock News & Opinions
Articles & Videos
Earnings
Orchid Pharma reports consolidated net loss of Rs 5.72 crore in the September 2025 quarter
Net loss of Orchid Pharma reported to Rs 5.72 crore in the quarter ended September 2025 as against net profit of Rs 27.24 crore during the previous quarter ended September 2024. Sales declined 13.10% to Rs 193.52 crore in the quarter ended September 2025 as against Rs 222.70 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales193.52222.70 -13 OPM %-0.7613.62 - PBDT5.5734.53 -84 PBT-3.3325.90 PL NP-5.7227.24 PL Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Orchid Pharma to hold board meeting
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Orchid Pharma schedules AGM
Orchid Pharma announced that the Annual General Meeting(AGM) of the company will be held on 20 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Orchid Pharma consolidated net profit declines 49.20% in the June 2025 quarter
Net profit of Orchid Pharma declined 49.20% to Rs 14.91 crore in the quarter ended June 2025 as against Rs 29.35 crore during the previous quarter ended June 2024. Sales declined 29.25% to Rs 172.93 crore in the quarter ended June 2025 as against Rs 244.41 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales172.93244.41 -29 OPM %8.1913.29 - PBDT22.3736.56 -39 PBT13.7128.12 -51 NP14.9129.35 -49 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Orchid Pharma announces board meeting date
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Orchid Pharma gets formal nod from Court of France for Allecra Therapeutics acquisition
On 30 July 2025, the company had announced the signing of an agreement with the Insolvency Administrator of Allecra Therapeutics GmbH (Germany) to purchase all assets (intellectual property, trademarks, customer contracts, regulatory filings and tangible/intangible assets) of Allecra Therapeutics GmbH (Germany). The Court in France in the hearing held on July 30 had accepted the company's binding bid that was being submitted in concurrence of the Insolvency Administrator of Allecra Therapeutics SAS for the acquisition of assets including Intellectual Property Rights and Trademarks of Allecra Therapeutics SAS. The formal pronouncement of Order was to be made in short period of time. We are hopeful to get the order in our favour,' Orchid Pharma had said in a statement. In an exchange filing made post trading hours yesterday, the company informed the Court of France has pronounced the order in favour of Orchid Pharma. Post this acquisition, Orchid Pharma now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This would mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. This consolidation via strategic asset acquisitions will provide growth and expansion across the globe to Orchid Brand and will be financially beneficial to the company,' Orchid Pharma had stated. Orchid Pharma is one of the leading pharmaceutical companies in India, headquartered in Chennai, and involved in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals, with exports spanning over 40 countries. The company's net profit declined 32.37% to Rs 22.29 crore despite a 9.39% rise in revenue to Rs 237.48 crore in Q4 FY25 as compared with Q4 FY24. The scrip fell 2.20% to currently trade at Rs 772 on the BSE. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Orchid Pharma schedules EGM
Orchid Pharma announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 26 June 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Orchid Pharma consolidated net profit declines 32.37% in the March 2025 quarter
Net profit of Orchid Pharma declined 32.37% to Rs 22.29 crore in the quarter ended March 2025 as against Rs 32.96 crore during the previous quarter ended March 2024. Sales rose 9.39% to Rs 237.48 crore in the quarter ended March 2025 as against Rs 217.10 crore during the previous quarter ended March 2024. For the full year,net profit rose 8.13% to Rs 99.66 crore in the year ended March 2025 as against Rs 92.17 crore during the previous year ended March 2024. Sales rose 12.52% to Rs 921.93 crore in the year ended March 2025 as against Rs 819.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales237.48217.10 9 921.93819.37 13 OPM %11.7813.32 -12.7113.51 - PBDT27.9738.80 -28 130.11125.18 4 PBT19.0930.38 -37 95.5691.95 4 NP22.2932.96 -32 99.6692.17 8 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Orchid Pharma to table results
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Orchid Pharma continues to be under rating watch with developing implications
Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintaining a rating watch with developing implications for bank facilities availed by the company. Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.32%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 0.2% to 0.23%